Forsta AP Fonden trimmed its stake in Colgate-Palmolive (NYSE:CL) by 64.7% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 45,966 shares of the company’s stock after selling 84,420 shares during the period. Forsta AP Fonden’s holdings in Colgate-Palmolive were worth $3,349,000 at the end of the most recent reporting period.
Several other hedge funds also recently modified their holdings of CL. OLD Second National Bank of Aurora bought a new position in Colgate-Palmolive in the 2nd quarter worth approximately $109,000. Krilogy Financial LLC increased its position in Colgate-Palmolive by 23.0% in the 2nd quarter. Krilogy Financial LLC now owns 1,547 shares of the company’s stock worth $115,000 after buying an additional 289 shares during the period. Hanson & Doremus Investment Management increased its position in Colgate-Palmolive by 4.5% in the 2nd quarter. Hanson & Doremus Investment Management now owns 1,630 shares of the company’s stock worth $121,000 after buying an additional 70 shares during the period. Captrust Financial Advisors bought a new position in Colgate-Palmolive in the 2nd quarter worth approximately $122,000. Finally, Harbour Capital Advisors LLC bought a new position in Colgate-Palmolive in the 1st quarter worth approximately $121,000. 72.84% of the stock is currently owned by institutional investors and hedge funds.
Several research analysts have commented on CL shares. Zacks Investment Research downgraded Colgate-Palmolive from a “buy” rating to a “hold” rating in a research report on Tuesday, September 26th. Jefferies Group reaffirmed a “hold” rating and issued a $79.00 price target on shares of Colgate-Palmolive in a research report on Thursday, September 28th. Morgan Stanley dropped their price target on Colgate-Palmolive from $84.00 to $83.00 and set an “overweight” rating on the stock in a research report on Tuesday, October 31st. KeyCorp reissued a “hold” rating on shares of Colgate-Palmolive in a report on Monday, October 16th. Finally, Macquarie started coverage on Colgate-Palmolive in a report on Thursday, September 14th. They set a “neutral” rating and a $76.00 price objective on the stock. Three equities research analysts have rated the stock with a sell rating, thirteen have given a hold rating and five have given a buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $76.33.
Colgate-Palmolive (NYSE CL) opened at $75.15 on Monday. The company has a debt-to-equity ratio of 24.42, a current ratio of 1.23 and a quick ratio of 0.92. The company has a market capitalization of $65,559.34, a price-to-earnings ratio of 29.02, a price-to-earnings-growth ratio of 3.42 and a beta of 0.81. Colgate-Palmolive has a one year low of $63.43 and a one year high of $77.27.
Colgate-Palmolive (NYSE:CL) last posted its quarterly earnings data on Friday, October 27th. The company reported $0.73 EPS for the quarter, hitting analysts’ consensus estimates of $0.73. The company had revenue of $3.97 billion for the quarter, compared to analyst estimates of $3.94 billion. Colgate-Palmolive had a return on equity of 2,782.56% and a net margin of 15.10%. The business’s revenue was up 2.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.73 earnings per share. sell-side analysts expect that Colgate-Palmolive will post 2.88 EPS for the current year.
Colgate-Palmolive Company (Colgate) is a consumer products company. The Company operates in two product segments: Oral, Personal and Home Care, and Pet Nutrition. The Oral, Personal and Home Care product segment is operated through five geographic segments, which include North America, Latin America, Europe, Asia Pacific and Africa/Eurasia.
Receive News & Ratings for Colgate-Palmolive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Colgate-Palmolive and related companies with MarketBeat.com's FREE daily email newsletter.